<DOC>
	<DOCNO>NCT00003816</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy drug total-body irradiation donor stem cell help stop growth cancer abnormal cell . It may also stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . It yet know combination chemotherapy regimen effective give donor stem cell transplant treat aplastic anemia hematologic cancer . PURPOSE : This phase II/III trial study different combination chemotherapy regimens compare well work give donor stem cell transplant treat patient aplastic anemia hematologic cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Donor Stem Cell Transplant Treating Patients With Aplastic Anemia Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare morbidity , mortality , overall outcome patient severe aplastic anemia hematologic malignancy treat standard v novel conditioning regimens follow allogeneic stem cell transplantation . - Examine influence donor histocompatibility outcome comparing matched/related , mismatched/related ( without T-cell depletion ) , matched/unrelated transplant stratification type preparative regimen . - Ensure patient uncommon diagnosis treat uniform fashion best therapy available . OUTLINE : Patients stratify accord risk relapse ( standard-risk : acute leukemia first complete remission , chronic myelogenous leukemia first chronic phase , lymphoma sensitive first relapse second remission , primary untreated myelodysplastic syndrome , untreated severe aplastic anemia vs high-risk : others ) . Patients assign one follow conditioning regimen base diagnosis , risk relapse , donor relatedness : - Regimen 1 : Patients receive busulfan IV 2 hour every 6 hour day -7 -4 cyclophosphamide IV 2 hour day -3 -2 . - Regimen 2 : Patients receive cyclophosphamide IV 2 hour day -5 -2 anti-thymocyte globulin IV 4-8 hour day -5 -3 . - Regimen 3 : Patients receive cyclophosphamide IV 2 hour day -5 -4 total-body irradiation ( TBI ) twice daily day -3 -1 . - Regimen 4 : Patients receive fludarabine IV 30 minute day -6 -2 melphalan IV 1 hour day -3 -2 . - Regimen 5 : Patients receive etoposide IV 26 hour begin day -5 , cyclophosphamide IV 2 hour day -4 , TBI twice daily day -3 -1 . - Regimen 6 : Patients receive cyclophosphamide IV 24 hour , carboplatin IV 24 hour , thiotepa IV 24 hour day -7 -4 . - Regimen 7 : Patients receive fludarabine IV 30 minute day -5 -1 anti-thymocyte globulin IV 4-8 hour day -5 -2 . - Regimen 8 : Patients receive cyclophosphamide IV 2 hour day -5 -4 , TBI twice daily day -3 -1 , anti-thymocyte globulin IV 4-8 hour day -3 -1 . - Regimen 9 : Patients receive busulfan IV 2 hour every 6 hour anti-thymocyte globulin IV 4-8 hour day -7 -4 cyclophosphamide IV 2 hour day -3 -2 . All patient receive donor stem cell infusion day 0 . Some patient may undergo involved-field radiotherapy 4-8 week transplant . Patients follow periodically post-transplant . PROJECTED ACCRUAL : At least 405 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Severe aplastic anemia define either follow : Marrow cellularity ( &lt; 25 % [ 2550 % cellularity &lt; 30 % remain cell hematopoietic origin ] ) At least 2 follow abnormal peripheral blood count : Reticulocyte count &lt; 1 % ( correct hematocrit ) Platelet count &lt; 20,000/mm^3 Neutrophil count &lt; 500/mm^3 Histologically confirm hematologic malignancy , include follow : Acute leukemia Resistant recurrent disease combination chemotherapy least one standard regimen OR first remission high risk relapse Acute myeloid leukemia ( AML ) ( antecedent myelodysplastic syndrome [ MDS ] , secondary AML , highrisk cytogenetic abnormality ) Acute lymphoblastic leukemia ( ALL ) ( highrisk cytogenetic abnormality ) Chronic myeloid leukemia ( CML ) Chronic phase , accelerated phase , blast phase Myeloproliferative disorder MDS , include follow : Myelofibrosis Polycythemia vera* Essential thrombocythemia* Refractory anemia Refractory anemia excess blast Refractory anemia excess blast transformation Chronic myelomonocytic leukemia NOTE : * Only transform AML MDS Lymphoproliferative disease Recurrent persistent , symptomatic disease firstline chemotherapy , include follow : Chronic lymphocytic leukemia ( CLL ) ( ≥ 20 % marrow involvement ) Waldenstrom macroglobulinemia Lowgrade nonHodgkin lymphoma Intermediate highgrade nonHodgkin lymphoma , meet 1 follow criterion : Resistant recurrent disease combination chemotherapy one standard regimen Lymphoblastic lymphoma small noncleaved cell lymphoma first remission high risk relapse CNS disease Bone marrow disease LDH great 300 Solid tumor would otherwise treat RPCIDS9115 ( equivalent autologous stem transplant protocol ) AND syngeneic donor Autologous bone marrow transplant possible ( desirable ) due 1 follow : History marrow tumor Inadequate marrow dose Abnormal marrow histology function prior storage Thrombocytopenia leukopenia Marrow cellularity &lt; 20 % Histocompatible donor identify Wellmatched donor , define 1 following : Family member match 5 6 HLA specificity ( A , B , DR ) * Unrelated donor meeting compatibility criteria National Marrow Donor Program ( match HLA A , B , DRB1 antigens ) * Identical twin sibling If compatible cord blood donor identify suitable unrelated donor available , patient may receive cord blood transplant NOTE : *Patients ≤ 25 year age may singly mismatch A B loci NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 4 70 Performance status : Zubrod 02 OR Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin &lt; 3 time normal ( unless due disease ) Alkaline phosphatase &lt; 3 time normal ( unless due disease ) SGOT &lt; 3 time normal ( unless due disease ) Hepatitis B surface antigen negative No severe hepatic disease would preclude study participation Renal : Creatinine normal Creatinine clearance ≥ 50 mL/min No severe renal disease would preclude study participation Cardiovascular : Cardiac ventricular ejection fraction ≥ 50 % MUGA echocardiogram No uncontrolled severe cardiovascular disease ( e.g. , myocardial infarction , congestive heart failure , symptomatic angina , life threaten arrhythmia , hypertension within past 6 month ) Pulmonary : DLCO DLVA ≥ 50 % predict ( correct hemoglobin alveolar ventilation ) Other : No serious concurrent medical psychiatric illness No serious organ dysfunction ( unless due underlie disease ) , include follow : Uncontrolled bacterial , viral , fungal infection Uncontrolled peptic ulcer disease Uncontrolled diabetes mellitus HIV negative Cytomegalovirus status know Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Pretransplant cytoreductive chemotherapy allow patient relapsed refractory disease Endocrine therapy : Not specify Radiotherapy : Not eligible totalbody irradiation prior radiotherapy exceed follow limit : Mediastinum : 3,600 cGy Heart : 3,600 cGy Whole lung : 1,200 cGy Small bowel : 3,600 cGy Kidneys : 1,200 cGy Whole liver : 1,600 cGy Cranial spinal : 3,600 cGy Brain : 4,000 cGy Retina : 4,000 cGy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>aplastic anemia</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>unspecified childhood solid tumor , protocol specific</keyword>
</DOC>